Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.33 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855089 | 0.84 | FERMT2 (0.35) | CCNCCDK8SHMT2MAPTKMT2A | |
| SCHEMBL944985 | 0.76 | HTT (0.41) | CCNCCDK8BACE1CCNB2CDK1 | |
| SCHEMBL1451142 | 0.76 | ALDH1A1 (0.41) | MAPTKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL4467255 | 0.76 | ALDH1A1 (0.46) | KMT2AKDM4EBACE1MEN1ALDH1A1 | |
| SCHEMBL4455873 | 0.76 | NR4A2 (0.43) | CCNCCDK8MAPTKMT2APARP1 | |
| SCHEMBL2472075 | 0.76 | DYRK1A (0.39) | CCNCCDK8KDM4EBACE1PARP1 | |
| SCHEMBL28141339 | 0.72 | NPC1 (0.41) | KMT2AMEN1CBFB | |
| SCHEMBL590041 | 0.72 | LMNA (0.43) | MAPTKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL5749391 | 0.72 | CDK5 (0.37) | CCNCCDK8ALDH1A1CCNB2CDK1 | |
| SCHEMBL5748480 | 0.72 | ALDH1A1 (0.34) | MAPTKMT2AKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114105960-A | Oxaadamantane derivatives capable of inhibiting activity of indoleamine 2, 3-dioxygenase | 齐鲁制药有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-113045488-A | Indoleamine 2, 3-dioxygenase inhibitors | 齐鲁制药有限公司 | 2021-06-29 | — | — | CN | claimed |
| WO-2019078968-A2 | CYCLIC COMPOUNDS AS IMMUNOMODULATING AGENTS | ANGEX PHARMACEUTICAL, INC. (US) | 2019-04-25 | — | — | WO | claimed |
| EP-2373641-B1 | PYRIDAZINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-12-19 | — | — | EP | claimed |
| US-8178538-B2 | Pyridazinones | HOFFMANN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | claimed |
| EP-2373641-A1 | PYRIDAZINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-10-12 | — | — | EP | claimed |
| US-20100152193-A1 | PYRIDAZINONES | HOFFMANN-LA ROCHE, INC. | 2010-06-17 | — | — | US | claimed |
| WO-2010063610-A1 | PYRIDAZINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | claimed |
| EP-3682873-B1 | SMAC MIMETICS FOR USE IN THE TREATMENT OF PERSISTENT HIV INFECTION | WALTER & ELIZA HALL INST MEDICAL RES (AU) | 2024-06-12 | — | — | EP | disclosed |
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220227762-A1 | AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | BEONE MEDICINES I GMBH (CH) | 2022-07-21 | — | — | US | disclosed |
| CN-114105960-A | Oxaadamantane derivatives capable of inhibiting activity of indoleamine 2, 3-dioxygenase | 齐鲁制药有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20220000847-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC (US) | 2022-01-06 | — | — | US | disclosed |
| CN-113891880-A | Amide substituted imidazo compounds as selective inhibitors of indoleamine 2, 3-dioxygenase | 百济神州有限公司 | 2022-01-04 | — | — | CN | disclosed |
| WO-2004024721-A1 | HYDANTOIN DERIVATIVES UND DEREN VERWENDUNG ALS TACE INHIBITOREN | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024698-A1 | 1-SULPHONYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
| WO-2004006926-A1 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ARYL OR HETEROARYL GROUP FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003011868-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003008422-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000847-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | CCNC 712/4885CDK8 610/4885SHMT2 674/4885 |
| US-11702401-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | CCNC 712/4885CDK8 610/4885SHMT2 674/4885 |
| US-20100152193-A1 | PYRIDAZINONES | PDE5A, PDE3A, PDE10A | CCNC 3799/4885CDK8 2342/4885SHMT2 2075/4885 |
| US-20220227762-A1 | AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | IDO1, IDO2, AADAC | CCNC 3697/4885CDK8 63/4885SHMT2 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.